{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:12:28Z","timestamp":1790190748482,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001826","name":"The Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","award":["1520020301"],"award-info":[{"award-number":["1520020301"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.nmd.2016.11.009","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T15:46:22Z","timestamp":1479483982000},"page":"259-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Ephedrine treatment for autoimmune myasthenia gravis"],"prefix":"10.1016","volume":"27","author":[{"given":"Alexander F.","family":"Lipka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Vrinten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik W.","family":"van Zwet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten J.M.","family":"Schimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina C.","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja R.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yechiel A.","family":"Hekster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie S.","family":"Weinreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.G.M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2016.11.009_bib0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2016.11.009_bib0015","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.1930.27120410003009c","article-title":"A report of progress on the use of ephedrine in a case of myasthenia gravis","volume":"94","author":"Edgeworth","year":"1930","journal-title":"J Am Med Assoc"},{"issue":"12","key":"10.1016\/j.nmd.2016.11.009_bib0020","article-title":"Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes","author":"Vrinten","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2016.11.009_bib0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.107.120709","article-title":"Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes","volume":"322","author":"Ma","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nmd.2016.11.009_bib0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0006-2952(99)00152-5","article-title":"Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes","volume":"58","author":"Vansal","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nmd.2016.11.009_bib0035","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/0028-3908(79)90017-0","article-title":"Ephedrine and neuromuscular transmission, in vivo","volume":"18","author":"Gallagher","year":"1979","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nmd.2016.11.009_bib0040","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0028-3908(79)90018-2","article-title":"Ephedrine: a postsynaptic depressant drug at the mammalian neuromuscular junction","volume":"18","author":"Shinnick-Gallagher","year":"1979","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nmd.2016.11.009_bib0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0006-8993(96)00894-3","article-title":"Block of the endplate acetylcholine receptor channel by the sympathomimetic agents ephedrine, pseudoephedrine, and albuterol","volume":"740","author":"Milone","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.nmd.2016.11.009_bib0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(93)90025-I","article-title":"Ephedrine: effects on neuromuscular transmission","volume":"623","author":"Sieb","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.nmd.2016.11.009_bib0055","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1212\/WNL.0b013e3181dd43bf","article-title":"Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7","volume":"74","author":"Lashley","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2016.11.009_bib0060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.nurt.2007.01.001","article-title":"The therapy of congenital myasthenic syndromes","volume":"4","author":"Engel","year":"2007","journal-title":"Neurother"},{"key":"10.1016\/j.nmd.2016.11.009_bib0065","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.expneurol.2013.06.012","article-title":"A mouse model of the slow channel myasthenic syndrome: neuromuscular physiology and effects of ephedrine treatment","volume":"248","author":"Webster","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nmd.2016.11.009_bib0070","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2377-13-132","article-title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","volume":"13","author":"Elsais","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2016.11.009_bib0075","first-page":"521","article-title":"A case report of myasthenia gravis associated with Hashimoto's thyroiditis","volume":"35","author":"Hashimoto","year":"1981","journal-title":"Folia Psychiatr Neurol Jpn"},{"key":"10.1016\/j.nmd.2016.11.009_bib0080","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2016.11.009_bib0085","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jclinepi.2010.04.020","article-title":"Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations","volume":"63","author":"Zucker","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.nmd.2016.11.009_bib0090","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jclinepi.2010.05.009","article-title":"Aggregating single patient (n-of-1) trials in populations where recruitment and retention was difficult: the case of palliative care","volume":"64","author":"Nikles","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.nmd.2016.11.009_bib0095","doi-asserted-by":"crossref","first-page":"e007863","DOI":"10.1136\/bmjopen-2015-007863","article-title":"Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials","volume":"5","author":"Vrinten","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.nmd.2016.11.009_bib0100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2016.11.009_bib0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2016.11.009_bib0110","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2016.11.009_bib0115","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2016.11.009_bib0120","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2016.11.009_bib0125","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mus.10224","article-title":"Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis","volume":"26","author":"Wolfe","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2016.11.009_bib0130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2016.11.009_bib0135","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2016.11.009_bib0140","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.289.12.1537","article-title":"Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis","volume":"289","author":"Shekelle","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2016.11.009_bib0145","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJM200012213432502","article-title":"Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids","volume":"343","author":"Haller","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2016.11.009_bib0150","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1073\/pnas.1524272113","article-title":"Sympathetic innervation controls homeostasis of neuromuscular junctions in health and disease","volume":"113","author":"Khan","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nmd.2016.11.009_bib0155","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1212\/WNL.0000000000001952","article-title":"Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes","volume":"85","author":"Rodriguez Cruz","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2016.11.009_bib0160","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.23.12.1273","article-title":"Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure","volume":"23","author":"Engel","year":"1973","journal-title":"Neurology"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616309440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616309440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:05:52Z","timestamp":1760774752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896616309440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0960896616309440"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2016.11.009","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ephedrine treatment for autoimmune myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2016.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}